# ADMA Biologics (ADMA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ADMA
## Company Profile
- Ticker: ADMA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Biologics
## Stock Data
- Close: 9.78 USD
- Market cap: 1761472634 USD
- Last updated: 2026-08-12
## Business Overview
### Plasma-Derived Biologics
ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection.
### ASCENIV
ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for patients with primary humoral immunodeficiency, including complex later-line cases.
### BIVIGAM and Manufacturing
BIVIGAM is a standard intravenous immunoglobulin product. ADMA controls plasma collection, fractionation, manufacturing and commercialization, allowing the company to manage supply and product mix internally.
### SG-001
SG-001 is a pneumococcal hyperimmune-globulin development program intended to use ADMA's existing plasma, manufacturing and commercial infrastructure for an infectious-disease product.
## Why The Stock Is Moving

As of Aug 12, 2026, ADMA closed down 1.26% at $9.78. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-05 20:05 EST — [ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADMA/adma-biologics-reports-second-quarter-2026-financial-results-and-provides-busine-af0e70d6) — Source: ADMA Biologics
- 2026-07-29 11:00 EST — [ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/ADMA/adma-biologics-to-report-second-quarter-2026-financial-results-on-august-5-2026-2950865d) — Source: ADMA Biologics
- 2026-05-06 20:05 EST — [ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADMA/adma-biologics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: ADMA Biologics
- 2026-05-04 11:00 EST — [ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older](https://biopharmsignal.com/news/ADMA/adma-biologics-announces-fda-approval-to-expand-the-label-for-ascenivtm-to-include-pediatric-immune-compromised-patients-two-years-of-age-and-older) — Source: ADMA Biologics
- 2026-04-29 11:00 EST — [ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026](https://biopharmsignal.com/news/ADMA/adma-biologics-to-report-first-quarter-2026-financial-results-on-may-6-2026) — Source: ADMA Biologics